Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 comparison of NCX 470 versus latanoprost in open-angle glaucoma or ocular hypertension
CTR20211277Phase 3Completed
- Sponsor
- Nicox S.A.
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of NCX 470 in open-angle glaucoma (OAG), ocular hypertension, sponsored by Nicox S.A.. Started Dec 2021; status: completed.
02
Drugs
NCX 470
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on CTR20211277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211277.